Following approval by the Food and Drug Administration (FDA) last year, the Centers for Medicare and Medicaid (CMS) proposed last month to cover the Alzheimer’s disease drug Aduhelm only for beneficiaries enrolled in a clinical trial. The proposal has sparked fierce debate among insurance groups, drugmakers, policymakers and the...
The Centers for Medicare and Medicaid Services (CMS) proposed Tuesday to cover the controversial drug Aduhelm when used as an Alzheimer’s treatment in clinical trials. While debate about the drug’s safety has been intense, CMS believes continued clinical trials will address unanswered questions related to the drug’s adverse side...CMS Rules
Proposing a rule to amend risk adjustment methodology for exchange plans, the Centers for Medicare and Medicaid Services (CMS) aims to improve the accuracy and effectiveness of the Affordable Care Act (ACA)-era program. The agency seeks to refine the program's error rate calculation and risk adjustment data validation (HHS-RADV)...Arizona News
On Monday, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule to lower prescription drug costs for beneficiaries by making changes to Medicare Part D. The proposal could give insurers negotiating powers on drug prices by offering an expectation that plans would implement broader use of prior authorization (PA)...National News
On Monday the Centers for Medicare and Medicaid Services (CMS) issued a proposal to relieve healthcare providers of Medicare's unnecessary compliance burdens.
According to the CMS press release, the updates would save healthcare providers approximately $1.12 billion annually.
CMS Administrator Seema Verma attributed this...
